Literature DB >> 15026475

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

Gordon J S Rustin, Michael Quinn, Tate Thigpen, Andreas du Bois, Eric Pujade-Lauraine, Anders Jakobsen, Elizabeth Eisenhauer, Satoru Sagae, Kathryn Greven, Ignace Vergote, Andres Cervantes, Jan Vermorken.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15026475     DOI： 10.1093/jnci/djh081

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  80 in total

1.  Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site.

Authors:  Rafael Molina; Xavier Bosch; Josep M Auge; Xavier Filella; José M Escudero; Víctor Molina; Manel Solé; Alfonso López-Soto
Journal:  Tumour Biol       Date:  2011-12-09

2.  A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.

Authors:  Mark A Morgan; Michael W Sill; Keiichi Fujiwara; Benjamin Greer; Stephen C Rubin; Koen Degeest; S Diane Yamada; Steven Waggoner; Robert L Coleman; Joan L Walker; Robert S Mannel
Journal:  Gynecol Oncol       Date:  2011-02-01       Impact factor: 5.482

3.  Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.

Authors:  David M Gershenson; Charlotte C Sun; Revathy B Iyer; Anais L Malpica; John J Kavanagh; Diane C Bodurka; Kathleen Schmeler; Michael Deavers
Journal:  Gynecol Oncol       Date:  2012-03-06       Impact factor: 5.482

4.  Tumour markers in internal medicine: a low-cost test or an unnecessary expense? A retrospective study based on appropriateness.

Authors:  D Arioli; M Pipino; E Boldrini; E Amateis; A Cristani; P Ventura; E Romagnoli; M C De Santis; M L Zeneroli
Journal:  Intern Emerg Med       Date:  2007-07-09       Impact factor: 3.397

5.  Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

Authors:  Thomas J Herzog; Deborah K Armstrong; Mark F Brady; Robert L Coleman; Mark H Einstein; Bradley J Monk; Robert S Mannel; J Tate Thigpen; Sharee A Umpierre; Jeannine A Villella; Ronald D Alvarez
Journal:  Gynecol Oncol       Date:  2013-11-15       Impact factor: 5.482

6.  Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.

Authors:  David M Hyman; Qin Zhou; Angela G Arnold; Rachel N Grisham; Alexia Iasonos; Noah D Kauff; David Spriggs
Journal:  Gynecol Oncol       Date:  2011-08-19       Impact factor: 5.482

7.  Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.

Authors:  Carin K Ingemarsdotter; Laura A Tookman; Ashley Browne; Katrina Pirlo; Rosalind Cutts; Claude Chelela; Karisma F Khurrum; Elaine Y L Leung; Suzanne Dowson; Lee Webber; Iftekhar Khan; Darren Ennis; Nelofer Syed; Tim R Crook; James D Brenton; Michelle Lockley; Iain A McNeish
Journal:  Mol Oncol       Date:  2014-12-29       Impact factor: 6.603

8.  Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.

Authors:  Setsuko K Chambers; H-H Sherry Chow; Mike F Janicek; Janiel M Cragun; Kenneth D Hatch; Haiyan Cui; Cynthia Laughren; Mary C Clouser; Janice L Cohen; Heather M Wright; Nisreen Abu Shahin; David S Alberts
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

9.  Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).

Authors:  Michael L Pearl; Huan Dong; Shaun Tulley; Qiang Zhao; Marc Golightly; Stanley Zucker; Wen-Tien Chen
Journal:  Gynecol Oncol       Date:  2015-03-11       Impact factor: 5.482

10.  Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.

Authors:  Karina Dahl Steffensen; Marianne Waldstrøm; Rikke Kølby Christensen; Annette Bartels; Nils Brünner; Anders Jakobsen
Journal:  BMC Cancer       Date:  2010-05-07       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.